Ipnolor (Lormetazepam)

Lormetazepam binds to the benzodiazepine site on the GABA‑A receptor, enhancing the inhibitory effect of the neurotransmitter GABA. This increases chloride ion flow into neurons, leading to hyperpolarisation, reduced neuronal excitability, and a calming effect that facilitates sleep.

The appropriate dose of Ipnolor is determined by the prescribing clinician based on the individual’s age, medical condition, and response to therapy. Dosage regimens are not standardized in public information and should follow the prescriber’s instructions.

Safety data for lormetazepam during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Ipnolor, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other benzodiazepine hypnotics such as temazepam or triazolam, lormetazepam has a relatively intermediate half‑life and may produce less next‑day sedation for some patients. However, all agents share similar risks of tolerance, dependence, and respiratory depression, so choice depends on individual response and physician judgment.

Ipnolor should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, light, and excessive heat. Do not store in the bathroom or near a kitchen sink where humidity is high.

Ipnolor is taken orally, usually with a glass of water. It is generally recommended to take the dose shortly before bedtime and to ensure a full night’s sleep opportunity (7‑8 hours) to minimise next‑day residual effects.

The most serious risks include the development of physical dependence, withdrawal seizures upon abrupt discontinuation, severe respiratory depression especially when combined with other CNS depressants, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of misuse or adverse reactions.

Ipnolor is contraindicated in patients with severe respiratory insufficiency, acute narrow‑angle glaucoma, myasthenia gravis, severe hepatic impairment, or known hypersensitivity to lormetazepam or other benzodiazepines. Caution is also advised for elderly individuals and those with a history of substance abuse.